Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,281.65 +4.14 (+0.08%) Dow
38,568.47 -117.85 (-0.30%) Nasdaq
16,827.16 +92.14 (+0.55%) Bitcoin USD
69,316.93 +964.58 (+1.41%) CMC Crypto 200
1,500.29 +32.35 (+2.20%)
IRWD Nov 2024 5.000 call
| Previous close | 1.6500 |
| Open | 3.2000 |
| Bid | 1.7500 |
| Ask | 2.4000 |
| Strike | 5.00 |
| Expiry date | 2024-11-15 |
| Day's range | 1.6500 - 3.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Business WireIronwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City.
Business WireIronwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
BOSTON, May 21, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present late-breaking data during the 2024 Digestive Disease Week® (DDW) meeting from its pivotal Phase III clinical trial, STARS, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in adult patients with short bowel syndrome with intestinal failure (SBS-IF). These findings build on the positive topline data that Ironwood previously announced in February 2024. B
Simply Wall St.US$16.33: That's What Analysts Think Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Is Worth After Its Latest Results
It's been a sad week for Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ), who've watched their investment drop 14% to...
